<DOC>
	<DOCNO>NCT01563536</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics , antiviral activity multiple , ascend dos ABT-267 ( also know ombitasvir ) administer two-day monotherapy follow ABT-267 combination therapy direct-acting antiviral agent ( DAAs ) ABT-450 ritonavir ( ABT-450/r ) ABT-333 ( also know dasabuvir ) plus ribavirin ( RBV ) patient chronic Hepatitis C virus ( HCV ) infection without cirrhosis .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics Antiviral Activity ABT-267 HCV Infected Subjects</brief_title>
	<detailed_description>An open-label , multicenter study evaluate safety , tolerability , pharmacokinetics , antiviral activity ABT-267 monotherapy 2 day , follow ABT-267 , ABT-450 ritonavir ( ABT-450/r ) ABT-333 plus ribavirin ( RBV ) combination therapy 12 week treatment-naïve , non-cirrhotic patient chronic hepatitis C virus ( HCV ) infection . The study include post-treatment follow-up 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male female age 18 70 year , inclusive , time enrollment . Subject never receive antiviral treatment hepatitis C virus ( HCV ) infection . Body mass index ( BMI ) ≥ 18 &lt; 38 kg/m^2 . BMI calculate weight measure kilogram ( kg ) divide square height measure meter ( ) . Chronic HCV genotype 1infection least 6 month prior study enrollment . Subject plasma HCV RNA level &gt; 10,000 IU/mL screen History severe , lifethreatening significant sensitivity drug . Females plan become pregnant breastfeeding male whose partner pregnant planning become pregnant . Recent history drug alcohol abuse could preclude adherence protocol . Positive test result hepatitis B surface antigen antihuman immunodeficiency virus ( HIV ) antibody . Any current past clinical evidence cirrhosis ( e.g. , ascites , esophageal varix ) , liver biopsy FibroTest/aspartate aminotransferase platelet ratio ( APRI ) FibroScan® show cirrhosis extensive bridging fibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hepatitis C , Genotype 1</keyword>
</DOC>